ArticleClinical, cosmetic and investigational dermatology2025
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Extracellular vesicle-like nanoparticles from Lactobacillus delbrueckii protect keratinocyte barrier function with involvement of TRPV4 signaling.World journal of microbiology & biotechnology · 2026Article
- Gram-Positive and Gram-Negative Probiotic Extracellular Vesicles: Mechanisms of Immune Modulation and Therapeutic Opportunities in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2026Review
- Extracellular Vesicles in Wearable Delivery Systems for Cosmeceutical Applications.Advanced healthcare materials · 2026Review
- Regenerative Approaches to Enhance the Skin Microenvironment and Boost Aesthetic Efficacy: A Narrative Review.International journal of molecular sciences · 2026Review
- Modulation of Moisturizing and Barrier Related Molecular Markers by Extracellular Vesicles Derived fromCurrent issues in molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The human skin, comprising the epidermis, dermis, and subcutaneous fat layers, serves as a critical barrier against external stimuli. The integrity of this barrier function is essential for preventing skin damage and diseases. When compromised, it can lead to various dermatological issues. Methods: This study investigated the efficacy of Results: In vitro experiments demonstrated that 2.5% LBDEs increased Filaggrin mRNA expression by 301.80% compared to the control. In an ex vivo skin damage model induced by physical stimulation and UVB (Ultraviolet B) irradiation, 1% LBDEs treatment significantly upregulated the expression of key barrier-related proteins, including Aquaporin-3 (180.8%), Claudin-1 (205.4%), Filaggrin (309.9%), Loricrin (365.2%), and Serine palmitoyltransferase (191.3%), in comparison to the friction and UVB-induced control group. Conclusion: These results suggest that LBDEs have potential in enhancing skin barrier function, as evidenced by increased expression of crucial barrier-related proteins in both in vitro and ex vivo models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.